ArticleIn vitro cellular & developmental biology. Animal2025
α-Cyperone affects the development and chemosensitivity of breast cancer by modulating TRIM24.
Article in In vitro cellular & developmental biology. Animal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) refers to a malignant neoplasm that takes place in the epithelial tissue of the breast. α-Cyperone (α-CYP) is one of the principal active components of Cyperus rotundus. However, research on the role of α-CYP in the development of BC is still lacking. This study investigates the effect and underlying mechanism of α-CYP in the progression of BC. Our findings revealed that both low-dose and high-dose α-CYP inhibited the colony formation ability of MCF-7 and BT474 cells, accompanied by the decrease in Ki67 expression and the obstruction of the cell cycle. Moreover, α-CYP treatment increased the activity of caspase-3, which leads to an increase in apoptosis. Moreover, the combination of α-CYP and cisplatin (DDP) remarkably suppressed cell viability and further facilitated apoptosis, indicating that α-CYP could enhance the sensitivity of chemotherapeutic agents in BC cells. Further, α-CYP treatment decreased TRIM24 expression through the ubiquitin-proteasome pathway. Notably, α-CYP counteracted the robust proliferation of BC cells triggered by TRIM24 overexpression. Taken together, this study confirmed that α-CYP is an effective anticancer component for BC treatment. α-CYP inhibits proliferation and induces apoptosis of BC cells via the modulation of TRIM24.
Indexed as
Identifiers
40634623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.